JNJ JOHNSON & JOHNSON
Pharmaceutical Preparations · NYSE · SEC CIK 200406 · Fiscal year ends 01/03
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.8%
TTM net income YoY-35.9%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR5.9%
Net income 3-yr CAGR-22.5%
Margins
Gross margin67.6%
Operating margin—
Net margin16.2%
FCF margin20.7%
EBITDA margin—
Returns
ROE20.0%
ROA8.2%
ROIC (approx.)—
Asset turnover0.51x
Leverage & solvency
Liabilities / assets58.7%
Debt / equity0.55x
Current ratio1.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.63x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-28 | FY20242024-12-29 |
|---|---|---|
| Income statement | ||
| Revenue | $94.19B | $88.82B |
| Cost of revenue | $30.26B | $27.47B |
| Gross profit | $63.94B | $61.35B |
| R&D expense | $109.00M | $1.84B |
| SG&A expense | $23.68B | $22.87B |
| Interest expense | $971.00M | $755.00M |
| Pretax income | $32.58B | $16.69B |
| Income tax | $5.78B | $2.62B |
| Net income | $26.80B | $14.07B |
| EPS (basic) | 11.13 | 5.84 |
| EPS (diluted) | 11.03 | 5.79 |
| Dividends declared per share | 5.14 | 4.91 |
| Weighted avg. shares (diluted) | 2.43B | 2.43B |
| Balance sheet | ||
| Cash & equivalents | $19.71B | $24.11B |
| Short-term investments | $393.00M | $417.00M |
| Receivables | $17.18B | $14.84B |
| Inventory | $14.19B | $12.44B |
| Current assets | $55.62B | $55.89B |
| PP&E, net | $23.17B | $20.52B |
| Goodwill | $48.77B | $44.20B |
| Intangibles | $50.40B | $37.62B |
| Total assets | $199.21B | $180.10B |
| Current liabilities | $54.13B | $50.32B |
| Short-term debt | $8.49B | $6.00B |
| Long-term debt | $39.44B | $30.65B |
| Total debt | $47.93B | $36.65B |
| Total liabilities | $117.67B | $108.61B |
| Shareholders' equity | $81.54B | $71.49B |
| Net debt | $28.22B | $12.55B |
| Cash flow statement | ||
| Operating cash flow | $24.53B | $24.27B |
| Capital expenditure | $4.83B | $4.42B |
| Free cash flow | $19.70B | $19.84B |
| Investing cash flow | -$23.59B | -$18.60B |
| Financing cash flow | -$5.54B | -$3.13B |
| Depreciation & amortization | $7.50B | $7.34B |
| Stock-based compensation | $1.35B | $1.18B |
| Share buybacks | $5.95B | $2.43B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.